Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
04:00pm, Tuesday, 26'th May 2026
Arcutis today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference, taking place June 8-10, 2026, in Miami.
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound
07:54am, Friday, 15'th May 2026
Arcutis Biotherapeutics (ARQT) is evolving into a specialized dermatology platform, leveraging ZORYVE's expanding indications, formulations, and prescriber base for compounding revenue growth. ARQT re
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 08'th May 2026
WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript
12:41am, Thursday, 07'th May 2026
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
06:25pm, Wednesday, 06'th May 2026
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.2 per share a year ago.
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
04:00pm, Wednesday, 06'th May 2026
Q1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 Continued strong demand for ZORYVE despite typical
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:01am, Thursday, 30'th Apr 2026
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
11:01am, Wednesday, 29'th Apr 2026
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis Once-daily ZORYVE cream was well to
Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitor
Comparing Quantum Biopharma (NASDAQ:QNTM) & Arcutis Biotherapeutics (NASDAQ:ARQT)
02:29am, Sunday, 19'th Apr 2026
Quantum Biopharma (NASDAQ: QNTM - Get Free Report) and Arcutis Biotherapeutics (NASDAQ: ARQT - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
04:00pm, Wednesday, 15'th Apr 2026
WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know
07:30am, Wednesday, 08'th Apr 2026
A director of Arcutis Biotherapeutics reported selling 10,000 shares for a total transaction value of $239,000 on April 1, 2026. This sale represented 20.10% of Howard G.
Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by JPMorgan Chase & Co.
04:45am, Wednesday, 08'th Apr 2026
JPMorgan Chase and Co. decreased its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) by 81.6% in the undefined quarter, according to its most recent Form 13F filing with the SEC. Th
